1. TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development
- Author
-
Stefan H. E. Kaufmann, Hazel M. Dockrell, Nick Drager, Mei Mei Ho, Helen McShane, Olivier Neyrolles, Tom H. M. Ottenhoff, Brij Patel, Danielle Roordink, François Spertini, Steffen Stenger, Jelle Thole, Frank A. W. Verreck, Ann Williams, TBVAC2020 Consortium, Warwick Britton, Jamie Triccas, Claudio Counoupas, Johan Grooten, Marie-Ange Demoitie, Marta Romano, Francoise Mascart, Peter Andersen, Claus Aagaard, Dennis Christensen, Morten Ruhwald, Thomas Lindenstrom, Pierre Charneau, Christophe Guilhot, Antonio Peixoto, Martine Gilleron, Camille Locht, Roland Brosch, Genevieve Inchauspe, Stephane Leung Theung Long, Stefan Kaufmann, January Weiner, Jeroen Maertzdorf, Natalie Neuwenhuizen, Max Bastian, Nadia Caccamo, Delia Goletti, Roberto Nisini, Sung Jae Shin, Hyejon Lee, Alex Sigal, Thomas Scriba, Gerhard Walzl, Andre Loxton, Robert Wilkinson, Pere-Joan Cardona, Cris Vilaplana, Carlos Martin, Dessi Marinova, Nacho Aguilo, Ruedi Aebersold, Etienne Caron, Daniel Pinschewer, Gennaro De Libero, Claire Anne Siegrist, Nicolas Collin, Christophe Barnier-Quer, Peter Sander, Frank Verreck, Tom Ottenhoff, Simone Joosten, Krista van Meijgaarden, Mariateresa Coppola, Annemieke Geluk, Yvonne Perrie, Marc Baird, Michael Levin, Hazel Dockrell, Steven Smith, Helen Fletcher, Gregory Bancroft, Ann Rawkins, Simon Clark, Iman Satti, Elena Stylianou, Martin Vordermeier, and Philip Hogarth
- Subjects
tuberculosis ,bacille Calmette–Guérin ,vaccination ,biomarker ,clinical trial ,portfolio management ,Immunologic diseases. Allergy ,RC581-607 - Abstract
TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.
- Published
- 2017
- Full Text
- View/download PDF